Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16380604 | 1.00 | NAAA (0.68) | NAAASMN1; SMN2HTTCYP2C19EPHX1 | |
| SCHEMBL16380552 | 0.98 | NAAA (0.69) | NAAASMN1; SMN2HTTCYP2C19EPHX1 | |
| SCHEMBL16380613 | 0.98 | NAAA (0.69) | NAAASMN1; SMN2HTTCYP2C19EPHX1 | |
| SCHEMBL27594966 | 0.88 | NAAA (0.65) | NAAASMN1; SMN2HTTCYP2C19EPHX1 | |
| SCHEMBL16376171 | 0.87 | NAAA (0.64) | NAAASMN1; SMN2HTTCYP2C19EPHX1 | |
| SCHEMBL16376178 | 0.87 | NAAA (0.64) | NAAASMN1; SMN2HTTCYP2C19EPHX1 | |
| SCHEMBL16432594 | 0.86 | NAAA (0.70) | NAAASMN1; SMN2HTTCYP2C19EPHX1 | |
| SCHEMBL16376173 | 0.86 | NAAA (0.65) | NAAASMN1; SMN2HTTCYP2C19EPHX1 | |
| SCHEMBL31069915 | 0.86 | NAAA (0.81) | NAAASMN1; SMN2HTTCYP2C19EPHX1 | |
| SCHEMBL3995658 | 0.85 | NAAA (0.61) | NAAASMN1; SMN2TSHRMETAP1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788316-B1 | BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-9463247-B2 | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | BANK OF AMERICA, N.A. | 2015-01-01 | — | — | US | disclosed |
| WO-2013086322-A1 | BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | LIPA, CETP, APOB | NAAA 1178/4885SMN1; SMN2 2502/4885HTT 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.